Amgen: Phase 3 Study Combining Kyprolis, Darzalex Met Primary Endpoint
December 10 2019 - 8:20AM
Dow Jones News
By Colin Kellaher
Amgen Inc. (AMGN) on Tuesday said a phase 3 study evaluating
Kyprolis in combination with dexamethasone and Darzalex met its
primary endpoint in patients with the blood cancer multiple
myeloma.
The Thousand Oaks, Calif., biotechnology company said the study
met its main endpoint of progression-free survival, resulting in a
37% reduction in the risk of disease progression or death in
patients with relapsed or refractory multiple myeloma.
Amgen said the combination also showed efficacy in key secondary
endpoints, including overall response rate and overall
survival.
Johnson & Johnson's (JNJ) Janssen Biotech Inc. unit has an
exclusive license to develop, manufacture and commercialize
Darzalex under an August 2012 agreement with Danish biotechology
company Genmab A/S (GMAB).
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 10, 2019 08:05 ET (13:05 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
